Find out the 4 FDA decisions to watch in November 2026 for pediatric care.

In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.

FDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.

In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.

New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.

Jessica Nash, MD, IBCLC, shares strategies for assessing breastfeeding, identifying latch problems, and connecting families with lactation resources.